Seeking Alpha

Progenics completes enrollment in mCRPC trial

  • Progenics Pharmaceuticals (PGNX +2.4%) completes enrollment in a Phase 2 study of PSMA ADC in metastatic castrate resistant prostate cancer.
  • The enrolled patients are chemotherapy experienced.
  • The company is also enrolling chemotherapy naive patients in a second cohort.
  • Top-line data from the chemotherapy experienced cohort is expected in January. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: